Investors

Welcome to our Investor Centre

Please click on the Profiles below to see more details on our other clients:

All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.

Renalytix plc

Company Profile

Company website
Sector
Medical Equipment and Services (Medical Equipment)
Description

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Investor Access

15 May
Event information

Management will be reporting its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open.

A corresponding conference call and live webcast will be held at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.

To register please click here: https://www.londonstockexchange.com/news-article/RENX/notice-of-q3-results/16461239.

Venue
Online
Time

Wednesday May 15 at 8:30 a.m. (ET) / 1:30 p.m. (BST)

Financial Calendar
 Event Date
Year End30 June
Half  Year End31 December
Preliminary Results*October
Interim Results*March
AGM*December

* Months based on previous announcements of this kind